Neuronal signaling by monoaminergic neurotransmitters controls all aspects of human autonomic functions and behavior, and dysregulation of this leads to many neuropsychiatric diseases. Nearly 60 years ago (Carlsson et al., 1957; Kirshner, 1962 ), secretory vesicles prepared from adrenal glands were shown to contain an activity that accumulated epinephrine, norepinephrine, and serotonin in an ATP-dependent manner (Eiden and Weihe, 2011). Extensive characterization by many different laboratories of synaptic vesicles (SVs) in neurons showed that monoamine transport activity was also dependent on the proton gradient generated by the V-ATPase, exchanging two protons for one cationic monoamine (Henry et al., 1998; Eiden, 2000; Johnson, 1988; Eiden et al., 2004; Schuldiner et al., 1995). Monoamine transport was shown to be inhibited by non-competitive inhibitors such as tetrabenazine (TBZ) (Peter et al., 1994) and competitive inhibitors like reserpine which has been used to treat hypertension (Eiden and Weihe, 2011). Amphetamines were shown to be monoamine transporter substrates, eventually leading to vesicle deacidification, disruption of dopamine (DA) packaging in the SV, and DA release into the synapse (Freyberg et al., 2016). Cloning of the vesicular monoamine transporter (VMAT) in the 1990s (Liu et al., 1992; Peter et al., 1995; Erickson et al., 1992) revealed two different genes, VMAT1 and VMAT2, that were expressed in the adrenal medulla and brain, respectively (Peter et al., 1995; Weihe et al., 1994). VMAT2 is expressed in all monoaminergic neurons in the brain, including those for serotonin, norepinephrine, DA, epinephrine, and histamine (Eiden and Weihe, 2011), and is essential for loading these neurotransmitters into SVs. VMAT2 is fundamentally required for neurotransmitter recycling and release (Wang et al., 1997; Takahashi et al., 1997; Fon et al., 1997) and changes in VMAT1 and VMAT2 activities either through small-molecule agents or mutations are thought to contribute to many human neuropsychiatric disorders including infantile-onset Parkinson’s, schizophrenia, alcoholism, autism, and bipolar depression (Lohoff et al., 2006; Vaht et al., 2016; Fehr et al., 2013; Bohnen et al., 2006; Han et al., 2020; Simons et al., 2013; Lohoff et al., 2008).

VMAT1 and -2 are members of the solute carrier 18 (SLC18) family and are also known as SLC18A1 and SLC18A2. The SLC18 subfamily also includes the vesicular transporters for acetylcholine (Arvidsson et al., 1997) (VAChT, SLC18A3) and polyamines (Hiasa et al., 2014) (VPAT, SLC18B1). Sequence alignments also show that SLC18 transporters belong to the major facilitator superfamily (MFS) of membrane transport proteins which use an alternating access mechanism (Jardetzky, 1966; Mitchell, 1957) to transport substrate across membranes. SLC18 members are predicted to be comprised of 12 transmembrane (TM) spanning helices (TM1–12), which are arranged in two pseudosymmetric halves each with six TM helices containing a primary binding site for neurotransmitters, polyamines, and inhibitors located approximately halfway across the membrane (Radestock and Forrest, 2011; Figure 1a). Conformational changes driven by the proton electrochemical gradient are thought to alternatively expose the binding site to either side of the membrane allowing for transport of neurotransmitter from the cytoplasm to the lumen of SVs (Yaffe et al., 2013; Yaffe et al., 2016).

Figure 1 with 3 supplements see all

Download asset Open asset

VMAT2 and VMAT1 share 62% sequence identity but have distinct substrate specificity and pharmacological properties (Erickson et al., 1996). Small-molecule ligands such as TBZ and reserpine are high-affinity inhibitors of VMAT2, which prevent neurotransmitters from binding, arrest VMAT2 from cycling, and consequently reduce neuronal signaling. VMAT2 exhibits higher affinity for TBZ, monoamines, and amphetamines, whereas reserpine binds equally to both VMAT2 and VMAT1 (Peter et al., 1994). TBZ is the only drug which is approved for treatment of chorea associated with Huntington’s disease and has shown to be effective in various other hyperkinetic conditions such as tardive dyskinesia, dystonia, tics, and Tourette’s syndrome (Kaur et al., 2016). A proposed mechanism for TBZ inhibition of VMAT2 involves two sequential steps, initial low-affinity binding of TBZ to the lumenal-open state of VMAT2 which produces a conformational change, resulting in a high-affinity dead-end TBZ-bound occluded complex (; Scherman et al., 1983; Scherman and Henry, 1984; Ugolev et al., 2013).

Here, we report a structure of VMAT2 bound to TBZ at 3.1 Å resolution in an occluded conformation using single-particle cryo-electron microscopy (cryo-EM), describing the architecture of VMAT2, identifying the high-affinity TBZ binding site, and revealing the mechanisms of drug and neurotransmitter binding, inhibition, and transport.

The VMAT2-TBZ complex captures the transporter in a fully occluded state with the ligand binding site centrally located between the two repeated substructures TM1–6 and TM7–12. VMAT2 functions by alternating access which involves alternate exposure of the primary binding site to either side of the membrane and isomerization between a cytosolic-open and lumenal-open state in a mechanism known as the rocker-switch (Figure 6a and b; Eiden and Weihe, 2011; Radestock and Forrest, 2011; Drew et al., 2021). Studies have proposed that TBZ first enters VMAT2 from the lumenal side, binding to a lumenal-open conformation (Scherman et al., 1983). TBZ makes extensive contact with residues in the primary site, likely in a lower affinity state as the transporter subsequently closes to forming the high-affinity occluded state. The lumenal gates lock the transporter into an occluded state, preventing displacement by other ligands and producing a so-called dead-end complex (Yaffe et al., 2016; Kaur et al., 2016; Scherman et al., 1983; Chen et al., 2012; Figure 6a).

Figure 6 with 2 supplements see all

Download asset Open asset

Comparison of the TMD with more distantly related MFS transporters in other conformational states such as the outward-open VGLUT2 (Li et al., 2020) and inward-open GLUT4 (Yuan et al., 2022) models (1.2 Å RMSD) shows that the conformational changes involving TM1, -7, -8, and -11 are likely involved in mediating the transport cycle and alternating access (Figure 6—figure supplement 1). Comparison with the AlphaFold model shows that while the TMD is largely similar (1.1 Å RMSD overall difference in TMD), AlphaFold lacks several key features such as the conformations of the LLs and is unable to predict key details that are critical to ligand binding. Hence, computational docking could not identify the TBZ binding site using the AlphaFold-predicted model, alluding to the critical importance of our experimental structural data (and simulations based on that structure) for gaining insights into VMAT2 functional mechanisms.

To enable us to solve the structure of VMAT2, we developed an intrinsic fiducial tool consisting of mVenus and the anti-GFP Nb which provides a feature on the cytosolic side of the transporter. GFP and the GFP-Nb are ubiquitous tools used for cell biology, protein biochemistry, and structural biology and here we describe another application of this powerful toolkit. In contrast to traditional antibody-based campaigns which may require multiple rounds of screening and take many months or years to discover a suitable binder, our strategy only required us to make between 15 and 20 constructs to find a suitable chimera (Figure 1—figure supplement 1a–c). There are now many other similar methods such as the fusion of the target protein with BRIL and binding of the anti-BRIL Fab (Mukherjee et al., 2020) and fusions of maltose-binding protein and DARPin (Chen et al., 2023). However, since our strategy directly incorporates fluorescent proteins, this enables FSEC-based screening of constructs and monitoring fluorescence throughout purification (Hattori et al., 2012). One obvious disadvantage of all intrinsic fiducial strategies is that the fusion may distort the protein structure, but monitoring the functional activity and comparison with the wild-type protein should mitigate these problems.

Among human mutations in VMAT2 causing an infantile-onset form of parkinsonism (Jacobsen et al., 2016; Rilstone et al., 2013; Padmakumar et al., 2019), three mutants, P316A, P237H, and P387L, have been shown to extinguish monoamine transport. We find these residues are in LL4 and the lumenal ends of TM5 and -9, respectively (Figure 6—figure supplement 2). LL4 is involved in lumenal gating and the P316A variant would likely disrupt the conformation of the loop. In the case of P237H, a histidine would result in not only an insertion of a positively charged residue into the lumenal membrane interface but also in a reduction of the helical bend and would distort the connection of TM5 with TM6. The P387L variant would also disrupt helical connections and the overall architecture of the helix by insertion of a bulky residue into a small hydrophobic cavity. Therefore, we speculate that these SNPs alter the transporter’s ability to sample multiple conformations by suppressing transporter dynamics and perturbing VMAT2 stability and folding. Recently, many additional disease variants have been discovered (Saida et al., 2023), many of which are also found in the lumenal or cytoplasmic ends of TM helices, LL1, and the N- and C-termini, and our structure will provide insight into the functional and structural consequences of these variants.

Large aromatic side chains of the lumenal gating residues compartmentalize the transporter, likely ensuring directional transport of substrate. MD simulations revealed little variation in the pose of the aromatic gating residues comprising the inner gates (Figure 4—figure supplement 2d). It is interesting to note that substitution of Y433 with alanine resulted in enhanced transport while reducing DTBZ binding. Reduced inhibitor binding is likely due to disruption of π-stacking interactions, but the mechanism for enhanced transport remains unclear. The lumenal gates showed more movement in MD simulations of DA, likely owing to its residue composition and lack of strong interactions (Figure 5). Despite this observation, we assert that the tight hydrophobic environment prevents exchange into the lumenal space. These mechanisms of gating are atypical of MFS transporters which more commonly use salt bridges to gate access to the substrate binding site (Drew et al., 2021).

Of particular interest among gating residues is W318, which acts as a central plug to prevent solvent access to the transporter. Our mutagenesis analysis suggests that while a large residue is required for maintaining some transporter function, lack of charge also appears to be essential for inhibitor binding. Replacement of W318 with residues present in VMAT2 from other species, except for the phenylalanine mutant, failed to recapitulate any DTBZ binding. Interestingly, of these substitutions, only an arginine was able to fully recapitulate native transport, suggesting lumenal gating activity requires either a large, charged or a large aromatic residue. Our studies also suggest that E127 plays a role in lumenal gating by interacting with LL4 as substitution to alanine-reduced transport, and we speculate that large, charged groups at position 318 directly interact with E127 to maintain full transporter function. In contrast, DBTZ binding remained unaffected for the E127A mutant, suggesting a role for this residue in a later step of transporter closure of the lumenal compartment. Positively charged residues at position 318 may stabilize the lumenal gate and promote conformational cycling through enhanced interactions with negatively charged residues such as E127 but may prevent TBZ from entering the lumenal pathway of the transporter in any capacity. Conservation of this residue in the SLC18 family suggests that this is a common mechanism for lumenal gating. It is unclear what other structural adaptations are present to enable W318 replacement with large positively charged residues in other VMAT2 sequences, but we suspect that the overall architecture of the lumenal domain remains similar. We also note that the disulfide bond between LL1 and -4 plays a critical role in transport (Yao and Hersh, 2007), and the disulfide bond may function to restrict the dynamics of this region to allow W318 to occlude the neurotransmitter binding site during transport.

Residues R189 and K138 stand out as critical for drug binding and inhibition and substrate transport. Simulations highlight the role K138 may play in coordinating with the hydroxy group of neurotransmitters and enabling binding at the central site. These results are consistent with previously observed results demonstrating the critical role K138 plays in substrate transport (Yaffe et al., 2013; Merickel et al., 1997). Remarkably, even mutation to lysine at position 189 abolishes DTBZ binding while still retaining a small amount of transport activity, highlighting the specificity of the DTBZ binding site.

Our structure also provides important clues for understanding the chemical specificity and selectivity of TBZ binding, suggesting that the enhanced affinity of DTBZ is due to preferential interaction with N34. DTBZ is a metabolite of TBZ (Chen et al., 2012) which differs by only a hydroxyl group vs. a double bonded oxygen and binds to VMAT2 with approximately twofold higher affinity (Saida et al., 2023; Yao et al., 2011; Figure 4a). Our structure suggests that the amide of N34 acts as a hydrogen bond donor for TBZ, and in the case of DTBZ the hydroxyl of the ligand may act as a hydrogen bond donor for the carbonyl oxygen of N34. We hypothesize that this interaction is more favorable for DTBZ, leading to a higher binding affinity. Valbenazine, a TBZ analogue with a valine attached to the oxygen of the hydroxyl group of DTBZ, binds VMAT2 with a K_d of 150 nM (Ugolev et al., 2013; Uhlyar and Rey, 2018). We hypothesize that N34 does not form a favorable hydrogen bond with the oxygen of valbenazine and that addition of this larger moiety causes steric clashes in the binding site. Mutation of N34 nearly eliminated DTBZ binding, highlighting its importance in coordinating inhibitor binding. We found N34 is also important for transport, but its precise role remains unclear. Strikingly, replacement with glutamine had no effect on transport whereas aspartate had only a small effect. This suggests that N34 is likely involved in substrate coordination but may not be entirely essential. This is confirmed with the N34A substitution which still showed significant transport activity. In contrast, a threonine substitution was greatly detrimental, but we believe this is likely due to larger active site perturbations.

Comparison of the residues involved in TBZ binding in VMAT2 vs. VMAT1 also provides insight into the selectivity of TBZ by demonstrating that key differences in the ligand binding site are likely responsible for the reduction in TBZ binding affinity observed in VMAT1 (Peter et al., 1994). L37 and V232 are highlighted, and mutation to the equivalent residue in VMAT1, phenylalanine, and leucine, respectively, eliminated DTBZ binding but only reduced substrate transport. Given these results, we suggest these are the primary residues involved in determining TBZ selectivity for VMAT2 vs. VMAT1. We suspect VMAT1 exhibits structural differences compared with VMAT2 to accommodate the larger residues and maintain functional activity.

Through MD simulations, we gained insights into the effects of the protonation states of TBZ and E312. Protonation of TBZ at the amine resulted in an unstable complex, and a structure markedly different from the state resolved with electron microscopy. This suggests TBZ remains unprotonated when bound to the occluded state, as the protonated form will not remain in complex with VMAT2. We believe there may be other TBZ-bound states such as the lumenal-open state where TBZ may be protonated. However, in the terminal complex, E312 must remain protonated suggesting that E312 acts as a hydrogen bond donor to stabilize TBZ in the binding site. Our binding and transport studies further confirm this as the mutation of E312 to glutamine greatly reduces serotonin transport and DTBZ binding (Figure 4f and g). Moreover, mutation of E312 to an alanine has long been known to completely negate all TBZ binding and transport activities (Yaffe et al., 2013; Støve et al., 2022) again highlighting the requirement of hydrogen bond pairing with TBZ.

We also highlight three key polar networks which may be involved in conformational changes induced by proton binding during the transport cycle and are likely also involved in mediating proton transduction (Figure 6a). Taken together, we believe these networks play a critical role in mediating the conformation changes taking place in the transporter upon substrate or inhibitor binding. We hypothesize that the protonation of D33, E312, D399, and D426 would significantly perturb these interactions by breaking crucial hydrogen bond pairs and/or salt bridges, leading to opening of the cytosolic gate. This falls in line with previous work highlighting the role these residues play in transport through a variety of mutagenesis and functional experiments (Merickel et al., 1997; Støve et al., 2022). Given the known transport stoichiometry of two protons per neurotransmitter, we speculate that two protons may dissociate back into the lumen, perhaps driven by the formation of salt bridges between D33 and K138 or R189 and E312 for example in an cytosol-facing state. The asymmetry between these two networks is also striking, with the first network consisting of TM1, -4, and -11 being substantially larger. This may allow for larger conformational changes on this side and an overall asymmetry in the cytosolic-open state of the transporter. To our knowledge, this is also an atypical feature in MFS proteins (Drew et al., 2021) and would represent an interesting adaptation upon the rocker-switch mechanism.

Our studies lead us to propose a mechanism by which TBZ inhibits VMAT2 by first entering the transporter from the lumenal-open state and subsequently trapping it in an occluded state through a two-step mechanism centered around W318, which acts as a central plug to close off the lumenal compartment. This provides a basis for non-competitive inhibition as endogenous neurotransmitter is unable to compete for binding from the closed off cytosolic compartment (Figure 6a). Our results also provide insight into transporter function, and we propose a mechanism for substrate release from the central binding site (Figure 6b). The bound substrate coordinates in the binding site predominantly through interactions with E312 and K138. R189 is directed toward the lumenal space where it engages with one of two water channels. Water enters through these channels into the transporter, passing F135 and F334 and inducing conformational change. In our simulations, we find intrusion of water to cause W318 to flip out of the central site which enables neurotransmitter to dissociate from the transporter (Figure 6b).

In summary, we have developed a new fiducial tool incorporating mVenus and the GFP-Nb into the primary sequence of a previously intractable transport protein of great importance to human health. Cryo-EM of VMAT2 allowed us to pinpoint the lumenal and cytoplasmic gates, polar networks likely involved in conformational change and proton transduction, and the conformation and binding site of inhibitors. Our structure facilitated the discovery and detailed analysis of many residues involved in these key molecular mechanisms and enabled further extension in our understanding of neurotransmitter transport. Thus, by capturing the VMAT2 bound with TBZ along with subsequent mutagenesis, binding, transport, and computational experiments, our work delivers insights into the transporter’s mechanism of function and provides a framework for understanding the structural underpinnings of neurotransmitter release, transport, and inhibition in VMAT2 and other related transport proteins in the MFS family.

The coordinates and associated volumes for the cryo-EM reconstruction of the VMAT2-TBZ data set have been deposited in the Protein Data Bank (PDB) and Electron Microscopy Data Bank (EMDB) under the accession codes 8THR and 41269.

1. 1. Dalton MP
   2. Coleman JA

   (2023) RCSB Protein Data Bank

   ID 8THR. Structure of the human vesicular monoamine transporter 2 (VMAT2) bound to tetrabenazine in an occluded conformation.

   https://www.rcsb.org/structure/8THR
2. 1. Dalton MP
   2. Coleman JA

   (2023) Electron Microscopy Data Bank

   ID EMD-41269. Structure of the human vesicular monoamine transporter 2 (VMAT2) bound to Tetrabenazine in an occluded conformation.

   https://www.ebi.ac.uk/emdb/EMD-41269

1. 1. Arvidsson U
   2. Riedl M
   3. Elde R
   4. Meister B

   (1997)

   Vesicular acetylcholine transporter (VAChT) protein: a novel and unique marker for cholinergic neurons in the central and peripheral nervous systems

   The Journal of Comparative Neurology 378:454–467.

   • PubMed
   • Google Scholar
2. 1. Bohnen NI
   2. Albin RL
   3. Koeppe RA
   4. Wernette KA
   5. Kilbourn MR
   6. Minoshima S
   7. Frey KA

   (2006) Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease

   Journal of Cerebral Blood Flow and Metabolism 26:1198–1212.

   https://doi.org/10.1038/sj.jcbfm.9600276

   • PubMed
   • Google Scholar
3. 1. Carlsson A
   2. Lindqvist M
   3. Manusson T

   (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists

   Nature 180:1200.

   https://doi.org/10.1038/1801200a0

   • PubMed
   • Google Scholar
4. 1. Chen JJ
   2. Ondo WG
   3. Dashtipour K
   4. Swope DM

   (2012) Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature

   Clinical Therapeutics 34:1487–1504.

   https://doi.org/10.1016/j.clinthera.2012.06.010

   • PubMed
   • Google Scholar
5. 1. Chen H
   2. Ahmed S
   3. Zhao H
   4. Elghobashi-Meinhardt N
   5. Dai Y
   6. Kim JH
   7. McDonald JG
   8. Li X
   9. Lee CH

   (2023) Structural and functional insights into Spns2-mediated transport of sphingosine-1-phosphate

   Cell 186:2644–2655.

   https://doi.org/10.1016/j.cell.2023.04.028

   • PubMed
   • Google Scholar
6. 1. Cheng MH
   2. Block E
   3. Hu F
   4. Cobanoglu MC
   5. Sorkin A
   6. Bahar I

   (2015) Insights into the modulation of dopamine transporter function by amphetamine, orphenadrine, and cocaine binding

   Frontiers in Neurology 6:134.

   https://doi.org/10.3389/fneur.2015.00134

   • PubMed
   • Google Scholar
7. 1. Cheng MH
   2. Kaya C
   3. Bahar I

   (2018) Quantitative assessment of the energetics of dopamine translocation by human dopamine transporter

   The Journal of Physical Chemistry. B 122:5336–5346.

   https://doi.org/10.1021/acs.jpcb.7b10340

   • PubMed
   • Google Scholar
8. 1. Chipot C
   2. Hénin J

   (2005) Exploring the free-energy landscape of a short peptide using an average force

   The Journal of Chemical Physics 123:244906.

   https://doi.org/10.1063/1.2138694

   • PubMed
   • Google Scholar
9. 1. Croll TI

   (2018) ISOLDE : a physically realistic environment for model building into low-resolution electron-density maps

   Acta Crystallographica Section D Structural Biology 74:519–530.

   https://doi.org/10.1107/S2059798318002425

   • Google Scholar
10. 1. Drew D
    2. North RA
    3. Nagarathinam K
    4. Tanabe M

    (2021) Structures and general transport mechanisms by the major facilitator superfamily (MFS)

    Chemical Reviews 121:5289–5335.

    https://doi.org/10.1021/acs.chemrev.0c00983

    • PubMed
    • Google Scholar
11. 1. Eiden LE

    (2000) The vesicular neurotransmitter transporters: current perspectives and future prospects

    FASEB Journal 14:2396–2400.

    https://doi.org/10.1096/fj.00-0817rev

    • PubMed
    • Google Scholar
12. 1. Eiden LE
    2. Schäfer MKH
    3. Weihe E
    4. Schütz B

    (2004) The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine

    Pflugers Archiv 447:636–640.

    https://doi.org/10.1007/s00424-003-1100-5

    • PubMed
    • Google Scholar
13. 1. Eiden LE
    2. Weihe E

    (2011) VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse

    Annals of the New York Academy of Sciences 1216:86–98.

    https://doi.org/10.1111/j.1749-6632.2010.05906.x

    • PubMed
    • Google Scholar
14. 1. Emsley P
    2. Cowtan K

    (2004) Coot: model-building tools for molecular graphics

    Acta Crystallographica. Section D, Biological Crystallography 60:2126–2132.

    https://doi.org/10.1107/S0907444904019158

    • PubMed
    • Google Scholar
15. 1. Erickson JD
    2. Eiden LE
    3. Hoffman BJ

    (1992) Expression cloning of a reserpine-sensitive vesicular monoamine transporter

    PNAS 89:10993–10997.

    https://doi.org/10.1073/pnas.89.22.10993

    • Google Scholar
16. 1. Erickson JD
    2. Schafer MK
    3. Bonner TI
    4. Eiden LE
    5. Weihe E

    (1996) Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter

    PNAS 93:5166–5171.

    https://doi.org/10.1073/pnas.93.10.5166

    • Google Scholar
17. 1. Essmann U
    2. Perera L
    3. Berkowitz ML
    4. Darden T
    5. Lee H
    6. Pedersen LG

    (1995) A smooth particle mesh Ewald method

    The Journal of Chemical Physics 103:8577–8593.

    https://doi.org/10.1063/1.470117

    • Google Scholar
18. 1. Fehr C
    2. Sommerlad D
    3. Sander T
    4. Anghelescu I
    5. Dahmen N
    6. Szegedi A
    7. Mueller C
    8. Zill P
    9. Soyka M
    10. Preuss UW

    (2013) Association of VMAT2 gene polymorphisms with alcohol dependence

    Journal of Neural Transmission 120:1161–1169.

    https://doi.org/10.1007/s00702-013-0996-y

    • PubMed
    • Google Scholar
19. 1. Fon EA
    2. Pothos EN
    3. Sun BC
    4. Killeen N
    5. Sulzer D
    6. Edwards RH

    (1997) Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action

    Neuron 19:1271–1283.

    https://doi.org/10.1016/s0896-6273(00)80418-3

    • PubMed
    • Google Scholar
20. 1. Freyberg Z
    2. Sonders MS
    3. Aguilar JI
    4. Hiranita T
    5. Karam CS
    6. Flores J
    7. Pizzo AB
    8. Zhang Y
    9. Farino ZJ
    10. Chen A
    11. Martin CA
    12. Kopajtic TA
    13. Fei H
    14. Hu G
    15. Lin YY
    16. Mosharov EV
    17. McCabe BD
    18. Freyberg R
    19. Wimalasena K
    20. Hsin LW
    21. Sames D
    22. Krantz DE
    23. Katz JL
    24. Sulzer D
    25. Javitch JA

    (2016) Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain

    Nature Communications 7:10652.

    https://doi.org/10.1038/ncomms10652

    • PubMed
    • Google Scholar
21. 1. Goehring A
    2. Lee C-H
    3. Wang KH
    4. Michel JC
    5. Claxton DP
    6. Baconguis I
    7. Althoff T
    8. Fischer S
    9. Garcia KC
    10. Gouaux E

    (2014) Screening and large-scale expression of membrane proteins in mammalian cells for structural studies

    Nature Protocols 9:2574–2585.

    https://doi.org/10.1038/nprot.2014.173

    • PubMed
    • Google Scholar
22. 1. Green EM
    2. Coleman JA
    3. Gouaux E

    (2015) Thermostabilization of the human serotonin transporter in an antidepressant-bound conformation

    PLOS ONE 10:e0145688.

    https://doi.org/10.1371/journal.pone.0145688

    • PubMed
    • Google Scholar
23. 1. Han H
    2. Xia X
    3. Zheng H
    4. Zhao C
    5. Xu Y
    6. Tao J
    7. Wang X

    (2020) The Gene Polymorphism of VMAT2 Is Associated with risk of schizophrenia in male han chinese

    Psychiatry Investigation 17:1073–1078.

    https://doi.org/10.30773/pi.2020.0023

    • PubMed
    • Google Scholar
24. 1. Hattori M
    2. Hibbs RE
    3. Gouaux E

    (2012) A fluorescence-detection size-exclusion chromatography-based thermostability assay for membrane protein precrystallization screening

    Structure 20:1293–1299.

    https://doi.org/10.1016/j.str.2012.06.009

    • PubMed
    • Google Scholar
25. 1. Henry JP
    2. Sagné C
    3. Bedet C
    4. Gasnier B

    (1998) The vesicular monoamine transporter: from chromaffin granule to brain

    Neurochemistry International 32:227–246.

    https://doi.org/10.1016/s0197-0186(97)00092-2

    • PubMed
    • Google Scholar
26. 1. Hiasa M
    2. Miyaji T
    3. Haruna Y
    4. Takeuchi T
    5. Harada Y
    6. Moriyama S
    7. Yamamoto A
    8. Omote H
    9. Moriyama Y

    (2014) Identification of a mammalian vesicular polyamine transporter

    Scientific Reports 4:6836.

    https://doi.org/10.1038/srep06836

    • PubMed
    • Google Scholar
27. 1. Hoover WG

    (1985) Canonical dynamics: Equilibrium phase-space distributions

    Physical Review. A, General Physics 31:1695–1697.

    https://doi.org/10.1103/physreva.31.1695

    • PubMed
    • Google Scholar
28. 1. Huang J
    2. Rauscher S
    3. Nawrocki G
    4. Ran T
    5. Feig M
    6. de Groot BL
    7. Grubmüller H
    8. MacKerell AD Jr

    (2017) CHARMM36m: an improved force field for folded and intrinsically disordered proteins

    Nature Methods 14:71–73.

    https://doi.org/10.1038/nmeth.4067

    • PubMed
    • Google Scholar
29. 1. Humphrey W
    2. Dalke A
    3. Schulten K

    (1996) VMD: visual molecular dynamics

    Journal of Molecular Graphics 14:33–38.

    https://doi.org/10.1016/0263-7855(96)00018-5

    • PubMed
    • Google Scholar
30. 1. Jacobsen JC
    2. Wilson C
    3. Cunningham V
    4. Glamuzina E
    5. Prosser DO
    6. Love DR
    7. Burgess T
    8. Taylor J
    9. Swan B
    10. Hill R
    11. Robertson SP
    12. Snell RG
    13. Lehnert K

    (2016) Brain dopamine-serotonin vesicular transport disease presenting as a severe infantile hypotonic parkinsonian disorder

    Journal of Inherited Metabolic Disease 39:305–308.

    https://doi.org/10.1007/s10545-015-9897-6

    • PubMed
    • Google Scholar
31. 1. Jardetzky O

    (1966) Simple allosteric model for membrane pumps

    Nature 211:969–970.

    https://doi.org/10.1038/211969a0

    • PubMed
    • Google Scholar
32. 1. Johnson RG

    (1988) Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport

    Physiological Reviews 68:232–307.

    https://doi.org/10.1152/physrev.1988.68.1.232

    • PubMed
    • Google Scholar
33. 1. Jumper J
    2. Evans R
    3. Pritzel A
    4. Green T
    5. Figurnov M
    6. Ronneberger O
    7. Tunyasuvunakool K
    8. Bates R
    9. Žídek A
    10. Potapenko A
    11. Bridgland A
    12. Meyer C
    13. Kohl SAA
    14. Ballard AJ
    15. Cowie A
    16. Romera-Paredes B
    17. Nikolov S
    18. Jain R
    19. Adler J
    20. Back T
    21. Petersen S
    22. Reiman D
    23. Clancy E
    24. Zielinski M
    25. Steinegger M
    26. Pacholska M
    27. Berghammer T
    28. Bodenstein S
    29. Silver D
    30. Vinyals O
    31. Senior AW
    32. Kavukcuoglu K
    33. Kohli P
    34. Hassabis D

    (2021) Highly accurate protein structure prediction with AlphaFold

    Nature 596:583–589.

    https://doi.org/10.1038/s41586-021-03819-2

    • PubMed
    • Google Scholar
34. 1. Kaur N
    2. Kumar P
    3. Jamwal S
    4. Deshmukh R
    5. Gauttam VT

    (2016) Tetrabenazine: Spotlight on drug review

    Annals of Neurosciences 23:176–185.

    https://doi.org/10.1159/000449184

    • Google Scholar
35. 1. Kaynak BT
    2. Bahar I
    3. Doruker P

    (2020) Essential site scanning analysis: A new approach for detecting sites that modulate the dispersion of protein global motions

    Computational and Structural Biotechnology Journal 18:1577–1586.

    https://doi.org/10.1016/j.csbj.2020.06.020

    • PubMed
    • Google Scholar
36. 1. Kirshner N

    (1962)

    Uptake of catecholamines by a particulate fraction of the adrenal medulla

    The Journal of Biological Chemistry 237:2311–2317.

    • PubMed
    • Google Scholar
37. 1. Klauda JB
    2. Venable RM
    3. Freites JA
    4. O’Connor JW
    5. Tobias DJ
    6. Mondragon-Ramirez C
    7. Vorobyov I
    8. MacKerell AD Jr
    9. Pastor RW

    (2010) Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types

    The Journal of Physical Chemistry. B 114:7830–7843.

    https://doi.org/10.1021/jp101759q

    • PubMed
    • Google Scholar
38. 1. Kremers GJ
    2. Goedhart J
    3. van Munster EB
    4. Gadella TJ

    (2006) Cyan and yellow super fluorescent proteins with improved brightness, protein folding, and FRET Förster radius

    Biochemistry 45:6570–6580.

    https://doi.org/10.1021/bi0516273

    • PubMed
    • Google Scholar
39. 1. Kubala MH
    2. Kovtun O
    3. Alexandrov K
    4. Collins BM

    (2010) Structural and thermodynamic analysis of the GFP:GFP-nanobody complex

    Protein Science 19:2389–2401.

    https://doi.org/10.1002/pro.519

    • PubMed
    • Google Scholar
40. 1. Lee J
    2. Cheng X
    3. Swails JM
    4. Yeom MS
    5. Eastman PK
    6. Lemkul JA
    7. Wei S
    8. Buckner J
    9. Jeong JC
    10. Qi Y
    11. Jo S
    12. Pande VS
    13. Case DA
    14. Brooks CL
    15. MacKerell AD
    16. Klauda JB
    17. Im W

    (2016) CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM simulations using the CHARMM36 additive force field

    Journal of Chemical Theory and Computation 12:405–413.

    https://doi.org/10.1021/acs.jctc.5b00935

    • PubMed
    • Google Scholar
41. 1. Le Guilloux V
    2. Schmidtke P
    3. Tuffery P

    (2009) Fpocket: an open source platform for ligand pocket detection

    BMC Bioinformatics 10:168.

    https://doi.org/10.1186/1471-2105-10-168

    • PubMed
    • Google Scholar
42. 1. Li F
    2. Eriksen J
    3. Finer-Moore J
    4. Chang R
    5. Nguyen P
    6. Bowen A
    7. Myasnikov A
    8. Yu Z
    9. Bulkley D
    10. Cheng Y
    11. Edwards RH
    12. Stroud RM

    (2020) Ion transport and regulation in a synaptic vesicle glutamate transporter

    Science 368:893–897.

    https://doi.org/10.1126/science.aba9202

    • PubMed
    • Google Scholar
43. 1. Liebschner D
    2. Afonine PV
    3. Baker ML
    4. Bunkóczi G
    5. Chen VB
    6. Croll TI
    7. Hintze B
    8. Hung L-W
    9. Jain S
    10. McCoy AJ
    11. Moriarty NW
    12. Oeffner RD
    13. Poon BK
    14. Prisant MG
    15. Read RJ
    16. Richardson JS
    17. Richardson DC
    18. Sammito MD
    19. Sobolev OV
    20. Stockwell DH
    21. Terwilliger TC
    22. Urzhumtsev AG
    23. Videau LL
    24. Williams CJ
    25. Adams PD

    (2019) Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix

    Acta Crystallographica Section D Structural Biology 75:861–877.

    https://doi.org/10.1107/S2059798319011471

    • Google Scholar
44. 1. Liu Y
    2. Peter D
    3. Roghani A
    4. Schuldiner S
    5. Privé GG
    6. Eisenberg D
    7. Brecha N
    8. Edwards RH

    (1992) A cDNA that suppresses MPP+ toxicity encodes A vesicular amine transporter

    Cell 70:539–551.

    https://doi.org/10.1016/0092-8674(92)90425-c

    • PubMed
    • Google Scholar
45. 1. Lohoff FW
    2. Dahl JP
    3. Ferraro TN
    4. Arnold SE
    5. Gallinat J
    6. Sander T
    7. Berrettini WH

    (2006) Variations in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) are associated with bipolar i disorder

    Neuropsychopharmacology 31:2739–2747.

    https://doi.org/10.1038/sj.npp.1301196

    • PubMed
    • Google Scholar
46. 1. Lohoff FW
    2. Weller AE
    3. Bloch PJ
    4. Buono RJ
    5. Doyle GA
    6. Ferraro TN
    7. Berrettini WH

    (2008) Association between polymorphisms in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) on chromosome 8p and schizophrenia

    Neuropsychobiology 57:55–60.

    https://doi.org/10.1159/000129668

    • PubMed
    • Google Scholar
47. 1. Lomize MA
    2. Pogozheva ID
    3. Joo H
    4. Mosberg HI
    5. Lomize AL

    (2012) OPM database and PPM web server: resources for positioning of proteins in membranes

    Nucleic Acids Research 40:D370–D376.

    https://doi.org/10.1093/nar/gkr703

    • PubMed
    • Google Scholar
48. 1. Mastronarde DN

    (2003) SerialEM: a program for automated tilt series acquisition on tecnai microscopes using prediction of specimen position

    Microscopy and Microanalysis 9:1182–1183.

    https://doi.org/10.1017/S1431927603445911

    • Google Scholar
49. 1. Merickel A
    2. Kaback HR
    3. Edwards RH

    (1997) Charged residues in transmembrane domains II and XI of a vesicular monoamine transporter form a charge pair that promotes high affinity substrate recognition

    The Journal of Biological Chemistry 272:5403–5408.

    https://doi.org/10.1074/jbc.272.9.5403

    • PubMed
    • Google Scholar
50. 1. Mitchell P

    (1957) A general theory of membrane transport from studies of bacteria

    Nature 180:134–136.

    https://doi.org/10.1038/180134a0

    • PubMed
    • Google Scholar
51. 1. Mukherjee S
    2. Erramilli SK
    3. Ammirati M
    4. Alvarez FJD
    5. Fennell KF
    6. Purdy MD
    7. Skrobek BM
    8. Radziwon K
    9. Coukos J
    10. Kang Y
    11. Dutka P
    12. Gao X
    13. Qiu X
    14. Yeager M
    15. Eric Xu H
    16. Han S
    17. Kossiakoff AA

    (2020) Synthetic antibodies against BRIL as universal fiducial marks for single−particle cryoEM structure determination of membrane proteins

    Nature Communications 11:1598.

    https://doi.org/10.1038/s41467-020-15363-0

    • Google Scholar
52. 1. Nosé S

    (1984) A molecular dynamics method for simulations in the canonical ensemble

    Molecular Physics 52:255–268.

    https://doi.org/10.1080/00268978400101201

    • Google Scholar
53. 1. O’Boyle NM
    2. Banck M
    3. James CA
    4. Morley C
    5. Vandermeersch T
    6. Hutchison GR

    (2011) Open Babel: An open chemical toolbox

    Journal of Cheminformatics 3:33.

    https://doi.org/10.1186/1758-2946-3-33

    • Google Scholar
54. 1. Olsson MHM
    2. Søndergaard CR
    3. Rostkowski M
    4. Jensen JH

    (2011) PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions

    Journal of Chemical Theory and Computation 7:525–537.

    https://doi.org/10.1021/ct100578z

    • PubMed
    • Google Scholar
55. 1. Padmakumar M
    2. Jaeken J
    3. Ramaekers V
    4. Lagae L
    5. Greene D
    6. Thys C
    7. Van Geet C
    8. BioResource N
    9. Stirrups K
    10. Downes K
    11. Turro E
    12. Freson K

    (2019) A novel missense variant in SLC18A2 causes recessive brain monoamine vesicular transport disease and absent serotonin in platelets

    JIMD Reports 47:9–16.

    https://doi.org/10.1002/jmd2.12030

    • PubMed
    • Google Scholar
56. 1. Pei J
    2. Kim BH
    3. Grishin NV

    (2008) PROMALS3D: a tool for multiple protein sequence and structure alignments

    Nucleic Acids Research 36:2295–2300.

    https://doi.org/10.1093/nar/gkn072

    • PubMed
    • Google Scholar
57. 1. Peter D
    2. Jimenez J
    3. Liu Y
    4. Kim J
    5. Edwards RH

    (1994)

    The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors

    The Journal of Biological Chemistry 269:7231–7237.

    • PubMed
    • Google Scholar
58. 1. Peter D
    2. Liu Y
    3. Sternini C
    4. de Giorgio R
    5. Brecha N
    6. Edwards RH

    (1995) Differential expression of two vesicular monoamine transporters

    The Journal of Neuroscience 15:6179–6188.

    https://doi.org/10.1523/JNEUROSCI.15-09-06179.1995

    • PubMed
    • Google Scholar
59. 1. Phillips JC
    2. Braun R
    3. Wang W
    4. Gumbart J
    5. Tajkhorshid E
    6. Villa E
    7. Chipot C
    8. Skeel RD
    9. Kalé L
    10. Schulten K

    (2005) Scalable molecular dynamics with NAMD

    Journal of Computational Chemistry 26:1781–1802.

    https://doi.org/10.1002/jcc.20289

    • PubMed
    • Google Scholar
60. 1. Punjani A
    2. Rubinstein JL
    3. Fleet DJ
    4. Brubaker MA

    (2017) cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination

    Nature Methods 14:290–296.

    https://doi.org/10.1038/nmeth.4169

    • PubMed
    • Google Scholar
61. 1. Punjani A
    2. Zhang H
    3. Fleet DJ

    (2020) Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction

    Nature Methods 17:1214–1221.

    https://doi.org/10.1038/s41592-020-00990-8

    • PubMed
    • Google Scholar
62. 1. Radestock S
    2. Forrest LR

    (2011) The alternating-access mechanism of MFS transporters arises from inverted-topology repeats

    Journal of Molecular Biology 407:698–715.

    https://doi.org/10.1016/j.jmb.2011.02.008

    • PubMed
    • Google Scholar
63. 1. Reeves PJ
    2. Callewaert N
    3. Contreras R
    4. Khorana HG

    (2002) Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line

    PNAS 99:13419–13424.

    https://doi.org/10.1073/pnas.212519299

    • PubMed
    • Google Scholar
64. 1. Rilstone JJ
    2. Alkhater RA
    3. Minassian BA

    (2013) Brain dopamine-serotonin vesicular transport disease and its treatment

    The New England Journal of Medicine 368:543–550.

    https://doi.org/10.1056/NEJMoa1207281

    • PubMed
    • Google Scholar
65. 1. Rothbauer U
    2. Zolghadr K
    3. Muyldermans S
    4. Schepers A
    5. Cardoso MC
    6. Leonhardt H

    (2008) A versatile nanotrap for biochemical and functional studies with fluorescent fusion proteins

    Molecular & Cellular Proteomics 7:282–289.

    https://doi.org/10.1074/mcp.M700342-MCP200

    • PubMed
    • Google Scholar
66. 1. Ryckaert JP
    2. Ciccotti G
    3. Berendsen HJC

    (1977) Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes

    Journal of Computational Physics 23:327–341.

    https://doi.org/10.1016/0021-9991(77)90098-5

    • Google Scholar
67. 1. Saida K
    2. Maroofian R
    3. Sengoku T
    4. Mitani T
    5. Pagnamenta AT
    6. Marafi D
    7. Zaki MS
    8. O’Brien TJ
    9. Karimiani EG
    10. Kaiyrzhanov R
    11. Takizawa M
    12. Ohori S
    13. Leong HY
    14. Akay G
    15. Galehdari H
    16. Zamani M
    17. Romy R
    18. Carroll CJ
    19. Toosi MB
    20. Ashrafzadeh F
    21. Imannezhad S
    22. Malek H
    23. Ahangari N
    24. Tomoum H
    25. Gowda VK
    26. Srinivasan VM
    27. Murphy D
    28. Dominik N
    29. Elbendary HM
    30. Rafat K
    31. Yilmaz S
    32. Kanmaz S
    33. Serin M
    34. Krishnakumar D
    35. Gardham A
    36. Maw A
    37. Rao TS
    38. Alsubhi S
    39. Srour M
    40. Buhas D
    41. Jewett T
    42. Goldberg RE
    43. Shamseldin H
    44. Frengen E
    45. Misceo D
    46. Strømme P
    47. Magliocco Ceroni JR
    48. Kim CA
    49. Yesil G
    50. Sengenc E
    51. Guler S
    52. Hull M
    53. Parnes M
    54. Aktas D
    55. Anlar B
    56. Bayram Y
    57. Pehlivan D
    58. Posey JE
    59. Alavi S
    60. Madani Manshadi SA
    61. Alzaidan H
    62. Al-Owain M
    63. Alabdi L
    64. Abdulwahab F
    65. Sekiguchi F
    66. Hamanaka K
    67. Fujita A
    68. Uchiyama Y
    69. Mizuguchi T
    70. Miyatake S
    71. Miyake N
    72. Elshafie RM
    73. Salayev K
    74. Guliyeva U
    75. Alkuraya FS
    76. Gleeson JG
    77. Monaghan KG
    78. Langley KG
    79. Yang H
    80. Motavaf M
    81. Safari S
    82. Alipour M
    83. Ogata K
    84. Brown AEX
    85. Lupski JR
    86. Houlden H
    87. Matsumoto N

    (2023) Brain monoamine vesicular transport disease caused by homozygous SLC18A2 variants: A study in 42 affected individuals

    Genetics in Medicine 25:90–102.

    https://doi.org/10.1016/j.gim.2022.09.010

    • PubMed
    • Google Scholar
68. 1. Sanchez-Garcia R
    2. Gomez-Blanco J
    3. Cuervo A
    4. Carazo JM
    5. Sorzano COS
    6. Vargas J

    (2021) DeepEMhancer: a deep learning solution for cryo-EM volume post-processing

    Communications Biology 4:874.

    https://doi.org/10.1038/s42003-021-02399-1

    • PubMed
    • Google Scholar
69. 1. Scheres SHW

    (2012) RELION: implementation of a Bayesian approach to cryo-EM structure determination

    Journal of Structural Biology 180:519–530.

    https://doi.org/10.1016/j.jsb.2012.09.006

    • PubMed
    • Google Scholar
70. 1. Scherman D
    2. Jaudon P
    3. Henry JP

    (1983) Characterization of the monoamine carrier of chromaffin granule membrane by binding of [2-3H]dihydrotetrabenazine

    PNAS 80:584–588.

    https://doi.org/10.1073/pnas.80.2.584

    • Google Scholar
71. 1. Scherman D
    2. Henry JP

    (1984)

    Reserpine binding to bovine chromaffin granule membranes: characterization and comparison with dihydrotetrabenazine binding

    Molecular Pharmacology 25:113–122.

    • PubMed
    • Google Scholar
72. Book

    1. Schrödinger

    (2023)

    Schrödinger Release 2023-4: Maestro

    Schrödinger LLC.

    • Google Scholar
73. 1. Schuldiner S
    2. Shirvan A
    3. Linial M

    (1995) Vesicular neurotransmitter transporters: from bacteria to humans

    Physiological Reviews 75:369–392.

    https://doi.org/10.1152/physrev.1995.75.2.369

    • PubMed
    • Google Scholar
74. 1. Simons CJP
    2. van Winkel R
    3. GROUP

    (2013) Intermediate phenotype analysis of patients, unaffected siblings, and healthy controls identifies VMAT2 as a candidate gene for psychotic disorder and neurocognition

    Schizophrenia Bulletin 39:848–856.

    https://doi.org/10.1093/schbul/sbs067

    • Google Scholar
75. 1. Støve SI
    2. Skjevik ÅA
    3. Teigen K
    4. Martinez A

    (2022) Inhibition of VMAT2 by β2-adrenergic agonists, antagonists, and the atypical antipsychotic ziprasidone

    Communications Biology 5:1283.

    https://doi.org/10.1038/s42003-022-04121-1

    • PubMed
    • Google Scholar
76. 1. Takahashi N
    2. Miner LL
    3. Sora I
    4. Ujike H
    5. Revay RS
    6. Kostic V
    7. Jackson-Lewis V
    8. Przedborski S
    9. Uhl GR

    (1997) VMAT2 knockout mice: Heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity

    PNAS 94:9938–9943.

    https://doi.org/10.1073/pnas.94.18.9938

    • Google Scholar
77. 1. Thiriot DS
    2. Ruoho AE

    (2001) Mutagenesis and derivatization of human vesicle monoamine transporter 2 (VMAT2) cysteines identifies transporter domains involved in tetrabenazine binding and substrate transport

    The Journal of Biological Chemistry 276:27304–27315.

    https://doi.org/10.1074/jbc.M103947200

    • PubMed
    • Google Scholar
78. 1. Thiriot DS
    2. Sievert MK
    3. Ruoho AE

    (2002) Identification of human vesicle monoamine transporter (VMAT2) lumenal cysteines that form an intramolecular disulfide bond

    Biochemistry 41:6346–6353.

    https://doi.org/10.1021/bi015779j

    • PubMed
    • Google Scholar
79. 1. Trott O
    2. Olson AJ

    (2010) AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

    Journal of Computational Chemistry 31:455–461.

    https://doi.org/10.1002/jcc.21334

    • PubMed
    • Google Scholar
80. 1. Ugolev Y
    2. Segal T
    3. Yaffe D
    4. Gros Y
    5. Schuldiner S

    (2013) Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine

    The Journal of Biological Chemistry 288:32160–32171.

    https://doi.org/10.1074/jbc.M113.502971

    • PubMed
    • Google Scholar
81. 1. Uhlyar S
    2. Rey JA

    (2018)

    Valbenazine (Ingrezza): the first fda-approved treatment for tardive dyskinesia

    P T Peer-Rev. J. Formul. Manag 43:328–331.

    • Google Scholar
82. 1. Vaht M
    2. Kiive E
    3. Veidebaum T
    4. Harro J

    (2016) A functional vesicular monoamine transporter 1 (VMAT1) gene variant is associated with affect and the prevalence of anxiety, affective, and alcohol use disorders in a longitudinal population-representative birth cohort study

    The International Journal of Neuropsychopharmacology 19:pyw013.

    https://doi.org/10.1093/ijnp/pyw013

    • PubMed
    • Google Scholar
83. 1. Vangone A
    2. Schaarschmidt J
    3. Koukos P
    4. Geng C
    5. Citro N
    6. Trellet ME
    7. Xue LC
    8. Bonvin A

    (2019) Large-scale prediction of binding affinity in protein-small ligand complexes: the PRODIGY-LIG web server

    Bioinformatics 35:1585–1587.

    https://doi.org/10.1093/bioinformatics/bty816

    • PubMed
    • Google Scholar
84. 1. Vanommeslaeghe K
    2. Raman EP
    3. MacKerell AD

    (2012) Automation of the CHARMM General Force Field (CGenFF) II: assignment of bonded parameters and partial atomic charges

    Journal of Chemical Information and Modeling 52:3155–3168.

    https://doi.org/10.1021/ci3003649

    • PubMed
    • Google Scholar
85. 1. Wang YM
    2. Gainetdinov RR
    3. Fumagalli F
    4. Xu F
    5. Jones SR
    6. Bock CB
    7. Miller GW
    8. Wightman RM
    9. Caron MG

    (1997) Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine

    Neuron 19:1285–1296.

    https://doi.org/10.1016/s0896-6273(00)80419-5

    • PubMed
    • Google Scholar
86. 1. Wang RY-R
    2. Song Y
    3. Barad BA
    4. Cheng Y
    5. Fraser JS
    6. DiMaio F

    (2016) Automated structure refinement of macromolecular assemblies from cryo-EM maps using Rosetta

    eLife 5:e17219.

    https://doi.org/10.7554/eLife.17219

    • PubMed
    • Google Scholar
87. 1. Weihe E
    2. Schäfer MK
    3. Erickson JD
    4. Eiden LE

    (1994) Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat

    Journal of Molecular Neuroscience 5:149–164.

    https://doi.org/10.1007/BF02736730

    • PubMed
    • Google Scholar
88. 1. Wu EL
    2. Cheng X
    3. Jo S
    4. Rui H
    5. Song KC
    6. Dávila-Contreras EM
    7. Qi Y
    8. Lee J
    9. Monje-Galvan V
    10. Venable RM
    11. Klauda JB
    12. Im W

    (2014) CHARMM-GUI Membrane Builder toward realistic biological membrane simulations

    Journal of Computational Chemistry 35:1997–2004.

    https://doi.org/10.1002/jcc.23702

    • PubMed
    • Google Scholar
89. 1. Yaffe D
    2. Radestock S
    3. Shuster Y
    4. Forrest LR
    5. Schuldiner S

    (2013) Identification of molecular hinge points mediating alternating access in the vesicular monoamine transporter VMAT2

    PNAS 110:E1332–E1341.

    https://doi.org/10.1073/pnas.1220497110

    • Google Scholar
90. 1. Yaffe D
    2. Vergara-Jaque A
    3. Forrest LR
    4. Schuldiner S

    (2016) Emulating proton-induced conformational changes in the vesicular monoamine transporter VMAT2 by mutagenesis

    PNAS 113:E7390–E7398.

    https://doi.org/10.1073/pnas.1605162113

    • Google Scholar
91. 1. Yaffe D
    2. Forrest LR
    3. Schuldiner S

    (2018) The ins and outs of vesicular monoamine transporters

    The Journal of General Physiology 150:671–682.

    https://doi.org/10.1085/jgp.201711980

    • PubMed
    • Google Scholar
92. 1. Yamashita A
    2. Singh SK
    3. Kawate T
    4. Jin Y
    5. Gouaux E

    (2005) Crystal structure of a bacterial homologue of Na+/Cl--dependent neurotransmitter transporters

    Nature 437:215–223.

    https://doi.org/10.1038/nature03978

    • PubMed
    • Google Scholar
93. 1. Yang D
    2. Gouaux E

    (2021) Illumination of serotonin transporter mechanism and role of the allosteric site

    Science Advances 7:eabl3857.

    https://doi.org/10.1126/sciadv.abl3857

    • PubMed
    • Google Scholar
94. 1. Yao J
    2. Hersh LB

    (2007) The vesicular monoamine transporter 2 contains trafficking signals in both its N-glycosylation and C-terminal domains

    Journal of Neurochemistry 100:1387–1396.

    https://doi.org/10.1111/j.1471-4159.2006.04326.x

    • PubMed
    • Google Scholar
95. 1. Yao Z
    2. Wei X
    3. Wu X
    4. Katz JL
    5. Kopajtic T
    6. Greig NH
    7. Sun H

    (2011) Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors

    European Journal of Medicinal Chemistry 46:1841–1848.

    https://doi.org/10.1016/j.ejmech.2011.02.046

    • PubMed
    • Google Scholar
96. 1. Yariv B
    2. Yariv E
    3. Kessel A
    4. Masrati G
    5. Chorin AB
    6. Martz E
    7. Mayrose I
    8. Pupko T
    9. Ben-Tal N

    (2023) Using evolutionary data to make sense of macromolecules with a “face-lifted” ConSurf

    Protein Science 32:e4582.

    https://doi.org/10.1002/pro.4582

    • PubMed
    • Google Scholar
97. 1. Yuan Y
    2. Kong F
    3. Xu H
    4. Zhu A
    5. Yan N
    6. Yan C

    (2022) Cryo-EM structure of human glucose transporter GLUT4

    Nature Communications 13:2671.

    https://doi.org/10.1038/s41467-022-30235-5

    • Google Scholar
98. 1. Zhang S
    2. Krieger JM
    3. Zhang Y
    4. Kaya C
    5. Kaynak B
    6. Mikulska-Ruminska K
    7. Doruker P
    8. Li H
    9. Bahar I

    (2021) ProDy 2.0: increased scale and scope after 10 years of protein dynamics modelling with Python

    Bioinformatics 37:3657–3659.

    https://doi.org/10.1093/bioinformatics/btab187

    • Google Scholar

Author details

1. Michael P Dalton

   Department of Structural Biology, University of Pittsburgh, Pittsburgh, United States

   Contribution

   Conceptualization, Data curation, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0001-5296-5099

2. Mary Hongying Cheng

   Laufer Center for Physical and Quantitative Biology, and Department of Biochemistry and Cell Biology, School of Medicine, Stony Brook University, Stony Brook, United States

   Contribution

   Data curation, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0001-5833-8221

3. Ivet Bahar

   Laufer Center for Physical and Quantitative Biology, and Department of Biochemistry and Cell Biology, School of Medicine, Stony Brook University, Stony Brook, United States

   Contribution

   Supervision, Funding acquisition, Methodology, Project administration, Writing – review and editing

   Competing interests

   No competing interests declared

4. Jonathan A Coleman

   Department of Structural Biology, University of Pittsburgh, Pittsburgh, United States

   Contribution

   Conceptualization, Resources, Data curation, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing

   For correspondence

   coleman1@pitt.edu

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0003-0001-6195

• 2,691

  views

• 221

  downloads

• 4

  citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.